With rigorous economic research and practical policy solutions, we focus on the issues and institutions that are critical to global development. Explore our core themes and topics to learn more about our work.
In timely and incisive analysis, our experts parse the latest development news and devise practical solutions to new and emerging challenges. Our events convene the top thinkers and doers in global development.
The Aeras Global TB Vaccine Foundation of Bethesda, MD and The University of California, Los Angeles (UCLA) announced today that the two organizations had executed a non-exclusive license for a tuberculosis vaccine technology developed at UCLA.
Under the agreement, UCLA is providing Aeras with a non-exclusive license to develop and market UCLA's rBCG30 tuberculosis vaccine technology for use in the developing world. Aeras is a nonprofit organization dedicated to developing new TB vaccines and distributing them to people in areas of the world hardest hit by the disease.
Last week, Gavi, the Vaccine Alliance, completed a $7.5 billion replenishment to fund its work on immunization in the world’s poorest countries between now and 2020. Gavi’s next step is to ensure that the money is used as effectively as possible to save lives and improve health.